27th week of 2014 patent applcation highlights part 44 |
Patent application number | Title | Published |
20140186340 | Methods and Compositions for Normalization of Tumor Vasculature by Inhibition of LOXL2 - Disclosed herein are methods and compositions for increasing perfusion, reducing hypoxia, reducing permeability and increasing the integrity of vasculature; e.g., in a tumor. The compositions include inhibitors of the LOXL2 enzyme. In certain of the methods, a LOXL2 inhibitor is used in combination with, and facilitates the therapeutic activity of, an anti-neoplastic agent. | 2014-07-03 |
20140186341 | METHODS FOR IMPROVING DRUG EFFICACY - The present disclosure provides methods for improving drug efficacy in a patient having an obstructed airway in a lung. Such methods modulate nerve activity in the autonomic nervous system of a patient to reduce obstruction of an airway in a lung of the patient prior to administering a drug to the patient. These methods are especially useful in improving efficacies of bronchodilators in treating obstructive lung diseases, such as chronic obstructive pulmonary disease. | 2014-07-03 |
20140186342 | Compositions and Methods for Diagnosing and Treating Cancer - An isolated antibody that specifically binds to an extracellular domain of human DDR2 and has a therapeutic effect on a solid tumor is described. Also described is a method of treating cancer, the method comprising administering to a patient having a solid tumor an antibody of the present disclosure in a therapeutically effective amount. | 2014-07-03 |
20140186343 | COMPOSITION COMPRISING ANTIBODY THAT BINDS TO DOMAIN II OF HER2 AND ACIDIC VARIANTS THEREOF - A composition comprising a main species HER2 antibody that binds to domain II of HER2 and acidic variants thereof is described. Pharmaceutical formulations comprising the composition, and therapeutic uses for the composition are also disclosed. | 2014-07-03 |
20140186344 | ROLES FOR DUAL ENDOTHELIN-1/ANGIOTENSIN II RECEPTOR (DEAR) IN HYPERTENSION AND ANGIOGENESIS - The present application is directed to the identification of mutations and/or polymorphisms in the Dual Endothelin-1/Angiotensin II Receptor (Dear) that indicate susceptibility to, or show current affliction with, hypertension. Additionally, the present invention discloses methods for the modulation of angiogenesis via the regulation of Dear. | 2014-07-03 |
20140186345 | METHOD OF ADMINISTERING AN ANTIBODY - Disclosed is a method for treating a human having a disease associated with leukocyte infiltration of mucosal tissues, comprising administering to said human an effective amount of a human or humanized immunoglobulin or antigen-binding fragment thereof having binding specificity for α4β7 integrin. Preferably, no more than about 8 mg immunoglobulin or fragment per kg body weight are administered during a period of about one month. | 2014-07-03 |
20140186346 | METHODS OF TREATING PAIN USING AN IL-31RA OR OSMR-B ANTAGONIST - Use of antagonists to IL-31Ra and OSMRb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated. | 2014-07-03 |
20140186347 | EXTENDING TIME TO DISEASE PROGRESSION OR SURVIVAL IN CANCER PATIENTS - The present application describes extending time to disease progression or survival in a cancer patient, where the patient's cancer displays HER activation, by treating the patient with a HER dimerization inhibitor, such as pertuzumab. | 2014-07-03 |
20140186348 | HUMANIZED AND CHIMERIC ANTI-PROPERDIN ANTIBODIES - An isolated anti-properdin antibody or antigen binding portion thereof includes a heavy chain variable domain including the 3CDRs in SEQ ID NO: 1 and light chain variable domain including the 3CDRS in SEQ ID NO: 9. | 2014-07-03 |
20140186349 | HUMAN CDR-GRAFTED ANTIBODY AND ANTIBODY FRAGMENT THEREOF - A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of CCR4 and has a cytotoxic activity against a CCR4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient. | 2014-07-03 |
20140186350 | COMPOSITIONS AND METHODS FOR LONG ACTING MOLECULES - The invention relates, in part, to compositions and methods that utilize a peptide tag that binds to hemagglutanin (HA). The HA tag can be linked to a molecule such as a protein or nucleic acid which, when administered to the eye, results in an increase in ocular half-life and/or mean residence time, and or a decrease in ocular clearance of the protein or nucleic acid. The invention also encompasses methods for treating ocular disease, including retinal vascular disease, by administering a protein or nucleic acid linked to an HA peptide tag. | 2014-07-03 |
20140186351 | STABLE PHARMACEUTICAL LIQUID FORMULATIONS OF THE FUSION PROTEIN TNFR:Fc - The present invention relates to stable pharmaceutical liquid formulations of the fusion protein TNFR:Fc comprising different buffer systems and stabilizers. In particular, it could be demonstrated that the physical stability of TNFR:Fc is significantly improved by using a citrate buffer system and lysine as stabilizer. | 2014-07-03 |
20140186352 | ANTI-GRANULYSIN ANTIBODIES AND METHODS OF USE THEREOF - An anti-granulysin antibody, or an scFv or Fab fragment thereof, capable of binding to an epitope region from R64 to R113 of granulysin and capable of neutralizing an activity of granulysin. The antibody may contain a sequence selected from the sequences of SEQ ID NO:82 to SEQ ID NO:195, or the antibody may contain a sequence selected from the sequences of SEQ ID NO:39 to SEQ ID NO:76. The antibody may be a monoclonal antibody. A method for treating or preventing an unwanted immune response disorder includes administering to a subject in need thereof an effective amount of an anti-granulysin antibody capable of neutralizing the activity of granulysin. The unwanted immune response disorder may be SJS, TEN, or GVHD. | 2014-07-03 |
20140186353 | Treatment Of Inflammatory Diseases By Inhibiting Cold-Inducible RNA-Binding Protein (CIRP) - Disclosed are pharmaceutical compositions comprising a CIRP inhibitor. A method of treating a subject suffering from an inflammatory condition comprising administering to said subject a CIRP inhibitor is also described herein. | 2014-07-03 |
20140186354 | ANTI-HER3/HER4 ANTIBODIES BINDING TO THE BETA-HAIRPIN OF HER3 AND THE BETA-HAIRPIN OF HER4 - The invention relates to anti-HER3/HER4 antigen binding proteins, e.g. anti-HER3/HER4 antibodies, that bind to the beta-hairpin of HER3 and the beta-hairpin of HER4, methods for selecting these antigen binding proteins, their preparation and use as medicament. | 2014-07-03 |
20140186355 | Nucleic Acids Encoding Antibody Molecules Which Bind IL-17A and IL-17F - The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules. | 2014-07-03 |
20140186356 | COMBINATION OF A C-MET ANTAGONIST AND AN AMINOHETEROARYL COMPOUND FOR THE TREATMENT OF CANCER - The invention also relates to a composition comprising an antibody antagonist to c-Met and an aminoheteroaryl compound, particularly as a medicament. The present invention also comprises a pharmaceutical composition comprising said anti c-Met antibody and said aminoheteroaryl compound as combination products for simultaneous, separate or sequential use. The invention relates to the use of the composition of the invention for the treatment of cancer in a mammal. | 2014-07-03 |
20140186357 | METHOD FOR TREATMENT OF DEGENERATIVE BRAIN DISORDERS COMPRISING INHIBITOR OF SUM01 AND BACE1 INTERACTION AS AN ACTIVE INGREDIENT - A treatment method for degenerative brain disorders using a pharmaceutically effective dose of the inhibitor of SUMO1 (small ubiquitin-like modifier 1) and BACE1 (β-secretase) interaction, or the inhibitor of SUMO1 expression or activation is provided. More specifically, it was confirmed that SUMO1 increased BACE1 accumulation and Aβ generation, that is SUMO1 regulated BACE1 accumulation by interacting with BACE1, and BACE1 dileucine motif was involved in SUMO1-mediated BACE1 accumulation. In addition, SUMO1 protein induced autophagy in H4 cells, while SUMO1 depletion reduced LC3-II level. It was further confirmed that SUMO1 and LC3 were co-localized in the cortex of APP transgenic mice. As shown herein, a pharmaceutically effective dose of the inhibitor of SUMO1 and BACE1 interaction or the inhibitor of SUMO1 expression can be effectively used for the treatment of degenerative brain disorders. | 2014-07-03 |
20140186358 | HER3 ANTIBODIES BINDING TO THE BETA-HAIRPIN OF HER3 - The invention relates to anti-HER3 antigen binding proteins, e.g. anti-HER3 antibodies, that bind to the beta-hairpin of HER3, methods for selecting these antigen binding proteins, their preparation and use as medicament. | 2014-07-03 |
20140186359 | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PROPHYLAXIS OF CANCER - This invention provides an antibody targeting a cancer antigenic protein specifically expressed on the surface of cancer cells and use thereof as a therapeutic and/or preventive agent for cancer. More specifically, the present invention provides an antibody, or a fragment thereof which has immunological reactivity with a partial CAPRIN-1 polypeptide consisting of the amino acid sequence shown by SEQ ID NO: 5 or an amino acid sequence having 80% or higher sequence identity to the amino acid sequence, and a pharmaceutical composition for treatment and/or prevention of cancer comprising the same as an active ingredient. | 2014-07-03 |
20140186360 | PHOSPHORYLCHOLINE CONJUGATES AND CORRESPONDING ANTIBODIES - In subjects with hypertension, increases in intima-media thickness (IMT) at four years were less in subjects also having high autoantibodies particularly IgM, to phosphorylcholine. The presence or absence of autoantibodies, particularly IgM, against phosphrylcholine is thus related to an increased or decreased risk of developing ischemic cardiovascular diseases. A method to determining antibodies, particularly IgM antibodies, toward phosphorylcholine is proposed in this invention to identify subjects at risk of developing ischemic cardiovascular diseases. Animal experiments show that medium to high levels of antibodies, particularly IgM antibodies, can be detected in plasma after active immunization with a keyhole limpet hemocyanin (KLH)-phosphorylcholine conjugate. Pharmaceutical compositions comprising a phosphorylcholine conjugate or antibody preparations, for example a monoclonal antibody, with specificity to a phosphorylcholine conjugate is proposed as is use of these compositions as active or passive immunogens in the treatment or prevention of atherosclerosis. | 2014-07-03 |
20140186361 | Stable Aqueous Formulations of Adalimumab - The invention provides aqueous pharmaceutical adalimumab compositions suitable for long-term storage of adalimumab, methods of manufacture of these compositions, methods of administration, and kits containing same. | 2014-07-03 |
20140186362 | Anti-Interferon Gamma Antibodies And Methods Of Use Thereof - The invention relates to fully human antibodies, and fragments thereof, that bind to human interferon gamma (hIFNγ), thereby modulating the interaction between IFNγ and its receptor, IFNγ-R, and/or modulating the biological activities of IFNγ. The invention also relates to the use of such anti-IFNγ antibodies in the prevention or treatment of immune-related disorders and in the amelioration of a symptom associated with an immune-related disorder. | 2014-07-03 |
20140186363 | MAGEA3 BINDING ANTIBODIES - The present invention relates to MAGEA3 binding antibodies. | 2014-07-03 |
20140186364 | INHIBITION OF THE NT-3:TRKC BOUND AND ITS APPLICATION TO THE TREATMENT OF CANCER SUCH AS NEUROBLASTOMA - The subject matter of the present disclosure relates to an in vitro method for the screening of anti-cancer compounds based on the capacity for these compounds to interact with neurotrophin 3 (NT-3 or NT3), to the extracellular domain or TrkC receptor and/or to inhibit the dimerization of the intracellular domain of the TrkC receptor expressed in tumor cells, particularly in neuroblastoma. The disclosure also relates to a method for predicting the presence of metastatic cancer or a bad prognosis cancer, or for determining the efficiency of an anti-cancer treatment based on the measuring of the expression level of neurotrophin 3. The disclosure further comprises kits and compounds as a medicament for the treatment of neuroblastoma or cancer overexpressing neurotrophin 3 by the tumor cells. | 2014-07-03 |
20140186365 | ANTIBODIES THAT SPECIFICALLY BIND TO SERUM ALBUMIN WITHOUT INTERFERING WITH ALBUMIN'S CAPABILITY TO INTERACT WITH THE FCRN - Antibodies that specifically bind to an epitope on the serum albumin, including human and/or mouse serum albumin are provided. Nucleic acids encoding such antibodies and cells capable of expressing such antibodies are also provided. | 2014-07-03 |
20140186366 | METHOD FOR PREDICTING THE RISK OF DEVELOPING A COLONIC NEOPLASIA - The present invention relates to an in vitro method for determining whether a patient having hyperplastic polyps is at risk of developing a colonic neoplasia after resection of said hyperplastic polyps, said method comprising the step of determining the level of progastrin expression in a tissue sample of a hyperplastic polyp obtained from said patient. | 2014-07-03 |
20140186367 | METHODS AND COMPOSITIONS RELATED TO GLUCOCORTICOID RECEPTOR ANTAGONISTS AND BREAST CANCER - Embodiments of the invention are directed to methods of determining the prognosis of a breast cancer patient by evaluating the activity of the glucocorticoid receptor in tumor cells. Other embodiment include methods of treating breast cancer cells, particularly, chemo-resistant cells, with a glucocorticoid receptor antagonist and an anticancer agent or compound. | 2014-07-03 |
20140186368 | METHODS OF ADMINISTERING ANTI-TNFalpha ANTIBODIES - Methods of treating disorders in which TNFα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNFα (e.g., K | 2014-07-03 |
20140186369 | METHOD OF MODULATING NEOVASCULARIZATION - The invention provides a method of inhibiting neovascularization in a subject. The method comprises administering to the subject an agent that interferes with fibronectin (Fn) matrix assembly in an amount effective to inhibit neovascularization. The invention also provides a method of identifying an agent that inhibits neovascularization. The method comprises detecting fibronectin (Fn) matrix assembly by stimulated endothelial cells cultured in three-dimensional culture gel in the presence and absence of an agent. A decrease in Fn matrix assembly in the presence of the agent compared to Fn matrix assembly in the absence of the agent is indicative of an agent that inhibits neovascularization. Alternatively, the method of identifying an agent that inhibits neovascularization comprises detecting changes in nuclear architecture in stimulated endothelial cells cultured in three-dimensional culture gel in the presence and absence of an agent. A reduction in nuclear architecture organization identifies an agent that inhibits neovascularization. | 2014-07-03 |
20140186370 | VACCINIA VIRUS H3L AND B5R SPECIFIC MONOCLONAL ANTIBODIES AND METHODS OF MAKING AND USING SAME - The invention relates to antibodies and subsequences thereof that specifically bind to poxvirus B5R envelope protein, antibodies and subsequences thereof that specifically bind to poxvirus H3L envelope protein, and combinations thereof. | 2014-07-03 |
20140186371 | COMPOSITIONS AND METHODS FOR TREATING DISEASES OF PROTEIN AGGREGATION INVOLVING IC3B DEPOSITION - The invention provides antibodies that preferentially bind to iC3b relative to C3b. These antibodies serve to reduce the toxicity of this fragment and find use in treatment and prophylaxis of a variety of diseases associated with deposits of the fragment. | 2014-07-03 |
20140186372 | COMPOSITIONS TARGETING PKC-THETA AND USES AND METHODS OF TREATING PKC-THETA PATHOLOGIES, ADVERSE IMMUNE RESPONSES AND DISEASES - The invention relates to compositions, methods and uses of inhibitors of binding between PKCθ and CD28, and modulating an undesirable or aberrant immune response, disorder or disease, an inflammatory response, disorder or disease, inflammation or an autoimmune response, disorder or disease. Compositions include inhibitors of binding between PKCθ and CD28, which include, among others, PKCθ, CD28 and Lck sequences, subsequences, variants and modified forms, and polymorphisms. | 2014-07-03 |
20140186373 | ANTIBODY FORMULATION - Anti-BAFFR antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilisate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant, and/or a free amino acid. | 2014-07-03 |
20140186374 | MANIPULATION OF REGULATORY T CELL AND DC FUNCTION BY TARGETING NEURITIN GENE USING ANTIBODIES, AGONISTS AND ANTAGONISTS - We demonstrate herein that neuritin controls the homeostasis of regulatory T cells in an antigen dependent manner. Based on this discovery, we describe herein the application of neuritin as a therapeutic agent to manipulate antigen specific regulatory T cells in various disease settings is described. Thus manipulation of Treg cells and DCs through neuritin can be used to enhance immunotherapy of autoimmune diseases, cancer and infectious diseases, as well as enhance lymphocyte engraftment in settings of donor lymphocyte infusion, bone marrow transplant, as well as other types of transplants, and adoptive transfer. | 2014-07-03 |
20140186375 | Combination of Immuno Gene Therapy and Chemotherapy for Treatment of Cancer and Hyperproliferative Diseases - Pharmaceutical compositions comprising a nucleic acid, a gene delivery polymer, and at least one adjunctive chemotherapeutic drug for the treatment of mammalian cancer or hyperproliferative disorders and methods of using thereof for the treatment of mammalian cancer or hyperproliferative disorders by intratumoral, intraperitoneal or systemic injection. | 2014-07-03 |
20140186376 | Compositions and Methods for Inhibiting CCL3 - The present invention relates to the discovery that CCL3, through at least one of its receptors CCR1 and CCR5, plays a role in the pathologies associated with myeloid neoplasms. In various embodiments, the pathologies associated with myeloid neoplasms treatable by the compositions and methods of the invention described herein include, but are not limited to, at least one of osteoclast/osteoblast imbalance, inhibition of osteoblast function, bone loss, disregulation of the hematopoietic stem cell microenvironment, abnormal hematopoietic recovery, pancytopenia, anemia, thrombocytopenia, neutropenia, bicytopenia, and erythrocytopenia. Interfering with the interaction between CCL3 and its receptors, by targeting at least one of CCL3, CCR1, CCR5, diminishes the effects of pathologies associated with myeloid neoplasms. In various embodiments, the myeloid neoplasm is a myeloproliferative disorder, acute myeloid leukemia (AML), chronic myeloid leukemia (CML), chronic myelomonocytic leukemia (CMML), or myelodysplastic syndrome (MDS). | 2014-07-03 |
20140186377 | PROSTAGLANDIN E2 BINDING PROTEINS AND USES THEREOF - The present invention encompasses prostaglandin E | 2014-07-03 |
20140186378 | GLYCOLIPIDS AND ANALOGUES THEREOF AS ANTIGENS FOR NKT CELLS - This invention relates to immunogenic compounds which serve as ligands for NKT (natural killer T) cells and to methods of use thereof in modulating immune responses. | 2014-07-03 |
20140186379 | NOVEL MACROMOLECULE TRANSDUCTION DOMAINS AND METHODS FOR IDENTIFICATION AND USES THEREOF - The present invention discloses novel macromolecule transduction domain (MTD) peptides which facilitate the traverse of a biologically active molecule across the cell membrane. Also disclosed are polynucleotides encoding the MTD peptides, methods of identifying the MTD peptides; methods of genetically engineering a biologically active molecule to have cell permeability by using the MTD peptides, methods of importing a biologically active molecule into a cell by using the MTD peptides, and uses thereof. | 2014-07-03 |
20140186380 | IMMUNOTHERAPY WITH BINDING AGENTS - Binding agents that modulate the immune response are disclosed. The binding agents may include soluble receptors, polypeptides, and/or antibodies. Also disclosed are methods of using the binding agents for the treatment of diseases such as cancer. | 2014-07-03 |
20140186381 | EPITOPE PEPTIDES DERIVED FROM VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1 AND VACCINES CONTAINING THESE PEPTIDES - The present invention provides immunogenic peptides comprising the amino acid sequence of SEQ ID NO: 1, 2, 13, 32, and peptides comprising the above-mentioned amino acid sequences in which 1, 2, or several amino acids are substituted or added, and having cytotoxic T cell inducibility, and also provides drugs for treating or preventing tumors comprising these peptides. The peptides of this invention can be used as vaccines. | 2014-07-03 |
20140186382 | CODON-OPTIMIZED POLYNUCLEOTIDE-BASED VACCINES AGAINST HUMAN CYTOMEGALOVIRUS INFECTION - The invention is related to polynucleotide-based cytomegalovirus vaccines. In particular, the invention is plasmids operably encoding HCMV antigens, in which the naturally-occurring coding regions for the HCMV antigens have been modified for improved translation in human or other mammalian cells through codon optimization. HCMV antigens which are useful in the invention include, but are not limited to pp65, glycoprotein B (gB), IE1, and fragments, variants or derivatives of either of these antigens. In certain embodiments, sequences have been deleted, e.g., the Arg435-Lys438 putative kinase in pp65 and the membrane anchor and endocellular domains in gB. The invention is further directed to methods to induce an immune response to HCMV in a mammal, for example, a human, comprising delivering a plasmid encoding a codon-optimized HCMV antigen as described above. The invention is also directed to pharmaceutical compositions comprising plasmids encoding a codon-optimized HCMV antigen as described above, and further comprising adjuvants, excipients, or immune modulators. | 2014-07-03 |
20140186383 | NOVEL SIMIAN T-CELL LYMPHOTROPIC VIRUS - Disclosed are the simian T-cell lymphotropic virus type 3 subtype D (STLV-3 subtype D), isolated nucleic acid molecules encoding STLV-3 subtype D polypeptides, such as STLV-3 subtype D envelope, protease, polymerase, tax, rex, and capsid polypeptides, isolated polypeptides encoded by such nucleic acids. Methods are also disclosed for detecting STLV-3 subtype D, for example by detecting a STLV-3 subtype D nucleic acid or polypeptide in the sample. Accordingly, probes, primers, and antibodies for use in detecting STLV-3 subtype D nucleic acids or polypeptides are disclosed. Therapeutic compositions which include isolated nucleic acid molecules encoding a STLV-3 subtype D polypeptides or isolated polypeptides encoded by such nucleic acid molecules are also disclosed. | 2014-07-03 |
20140186384 | VACCINES AND METHODS FOR USING THE SAME - Improved anti-HIV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus sequences for HIV Subtype A Envelope protein, those having consensus sequences for HIV Subtype B Envelope protein, those having consensus sequences for HIV Subtype C Envelope protein, those having consensus sequences for HIV Subtype D Envelope protein, those having consensus sequences for HIV Subtype B consensus Nef-Rev protein, and those having consensus sequences form HIV Gag protein subtypes A, B, C and D. Improved anti-HPV immunogens and nucleic acid molecules that encode them; improved anti-HCV immunogens and nucleic acid molecules that encode them; improved hTERT immunogens and nucleic acid molecules that encode them; and improved anti-Influenza immunogens and nucleic acid molecules that encode them are disclosed as well methods of inducing an immune response in an individual against HIV, HPV, HCV, hTERT and Influenza are disclosed. | 2014-07-03 |
20140186385 | POTOMAC HORSE FEVER ISOLATES - The present invention discloses novel isolates of | 2014-07-03 |
20140186386 | METHODS FOR PREVENTING AND TREATING STAPHYLOCOCCUS AUREUS COLONIZATION, INFECTION, AND DISEASE - The invention provided herein relates to a method of preventing a | 2014-07-03 |
20140186387 | SIGNAL PEPTIDE FUSION PARTNERS FACILITATING LISTERIAL EXPRESSION OF ANTIGENIC SEQUENCES AND METHODS OF PREPARATION AND USE THEREOF - The present invention provides nucleic acids, expression systems, and vaccine strains which provide efficient expression and secretion of antigens of interest into the cytosol of host cells, and elicit effective CD4 and CD8 T cell responses by functionally linking Listerial or other bacterial signal peptides/secretion chaperones as N-terminal fusion partners in translational reading frame with selected recombinant encoded protein antigens. These N-terminal fusion partners are deleted (either by actual deletion, by mutation, or by a combination of these approaches) for any PEST sequences native to the sequence, and/or for certain hydrophobic residues. | 2014-07-03 |
20140186388 | Method for Producing Protein-Carbohydrate Vaccines Reduced in Free Carbohydrate - This invention is directed to processes for reducing the level of free carbohydrate from a solution of protein-linked carbohydrate (conjugate) and non-linked carbohydrate. In this process, the conjugate is adsorbed to a hydrophobic membrane while the carbohydrate is not. The conjugate is then desorbed from the membrane, yielding a solution that is substantially reduced in free carbohydrate. | 2014-07-03 |
20140186389 | CONJUGATION PROCESS OF BACTERIAL POLYSACCHARIDES TO CARRIER PROTEINS - Process for conjugation of bacterial saccharides including | 2014-07-03 |
20140186390 | CONJUGATION PROCESS OF BACTERIAL POLYSACCHARIDES TO CARRIER PROTEINS - Process for conjugation of bacterial saccharides including | 2014-07-03 |
20140186391 | VACCINE AGAINST RSV - Provided is a vaccine against respiratory syncytial virus (RSV), comprising a recombinant human adenovirus of serotype that comprises nucleic acid encoding a RSV F protein or immunologically active part thereof. | 2014-07-03 |
20140186392 | Interferon- Production Modulating Listeria Strains and Methods for Using Same | 2014-07-03 |
20140186393 | IMMUNOGENIC COMPOSITION COMPRISING MYCOPLASMA ANTIGENS - The present invention relates to an immunogenic composition comprising: a) one or more antigen of | 2014-07-03 |
20140186394 | METHOD OF MAKING A MYCOPLASMA VACCINE - The present invention relates to a method for the preparation of an immunogenic composition for the treatment and/or prophylaxis of | 2014-07-03 |
20140186395 | PERMISSIVE CELLS AND USES THEREOF - Described are methods for determining the permissiveness of a cell for a virus that is a member of the family Arteriviridae or Coronaviridae or Asfarviridae, in particular, for Porcine Reproductive and Respiratory Syndrome Virus (PRRSV). Further described are methods and compositions related to the generation of host cells permissive for a virus that is a member of the family Arteriviridae or Coronaviridae or Asfarviridae, in particular, for PRRSV. Methods of utilzing the cells thus identified or thus generated, in preparing a culture of a virus that is a member of the family Arteriviridae or Coronaviridae or Asfarviridae, as well as the use of the virus for the purpose of vaccine production or diagnosis, are also described. | 2014-07-03 |
20140186396 | METHODS FOR STABILIZING INFLUENZA ANTIGEN ENVELOPED VIRUS-BASED VIRUS-LIKE PARTICLE SOLUTIONS - Methods of stabilizing solutions with enveloped virus-based virus-like particles containing an influenza antigen and such stabilized solutions are described. | 2014-07-03 |
20140186397 | MODIFIED SENDAI VIRUS VACCINE AND IMAGING VECTOR - The present invention relates to a Sendai virus or recombinant Sendai virus vector. In particular the present invention provides methods, vectors, formulations, compositions, and kits for a modified Enders strain Sendai viral vector. An immunogenic vector can be used in any in vitro or in vivo system. Moreover, some embodiments include vectors for imaging virus growth, location and transmission. | 2014-07-03 |
20140186398 | BACTERIAL RNAs AS VACCINE ADJUVANTS - The disclosure features vaccine adjuvants comprising prokaryotic mRNA, and methods of vaccination using the adjuvants. More specifically, the disclosure provides a vaccine composition comprising a nonviable immunogen (e.g., heat-killed bacterium), a tumor antigen, or an immunogenic peptide of microbial or mammalian origin, and an adjuvant, wherein adjuvant comprises prokaryotic mRNA (e.g., bacterial mRNA), as well as the methods of using the vaccine compositions. Further disclosed are the structural features of the prokaryotic mRNA used as the adjuvants. | 2014-07-03 |
20140186399 | PROTEIN MATRIX VACCINES AND METHODS OF MAKING AND ADMINISTERING SUCH VACCINES - The invention relates to vaccine compositions having a carrier protein and an antigen of interest entrapped in a complex, methods of making such vaccines, and methods of vaccine administration. | 2014-07-03 |
20140186400 | METHODS AND COMPOSITIONS FOR TREATING AUTOIMMUNE DISEASES - The invention features methods for increasing or maintaining the number of functional cells of a predetermined type, for example, insulin producing cells of the pancreas, blood cells, spleen cells, brain cells, heart cells, vascular tissue cells, cells of the bile duct, or skin cells, in a mammal (e.g., a human patient) that has injured or damaged cells of the predetermined type. | 2014-07-03 |
20140186401 | TUMOR ASSOCIATED VACCINES AND COMPOSITIONS FOR DISRUPTING TUMOR-DERIVED IMMUNOSUPPRESSION FOR USE IN COMBINATION CANCER IMMUNOTHERAPY - In one embodiment, a single modality cancer immunotherapy regimen that includes a therapeutic composition is provided. Such a therapeutic composition may include a | 2014-07-03 |
20140186402 | Blood Stage Malaria Vaccine - An immunogenic composition for use as a blood-stage malaria vaccine, a method of producing the immunogenic composition and a method of treatment of malaria are provided. The immunogenic composition includes isolated or purified merozoites, or red blood cells infected with merozoites, treated with centanamycin or tafuramycin A. The immunogenic composition does not include an adjuvant. A single dose of the immunogenic composition is sufficient to protect an animal against subsequent malaria infection by the same isolate, strain or species of | 2014-07-03 |
20140186403 | PEPTIDE FOR VACCINE - The present invention relates to compositions comprising peptides for preventing or treating allergy to house dust mites, and in particular to optimal combinations of peptides for preventing or treating said allergy. | 2014-07-03 |
20140186404 | METHODS FOR TREATING MULTIPLE MYELOMA USING 4-(AMINO)-2-(2,6-DIOXO(3-PIPERIDYL))-ISOINDOLINE-1,3-DIONE IN COMBINATION WITH ANTIBODIES - Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed. | 2014-07-03 |
20140186405 | Processes for Packaging Oligonucleotides into Virus-Like Particles of RNA Bacteriophages - The invention provides processes for the producing compositions comprising (i) a virus-like particle, wherein said virus-like particle is a virus-like particle of an RNA bacteriophage, and (ii) an oligonucleotide, wherein said oligonucleotide is packaged into said virus-like particle. The invention further provides processes for producing nucleotide compositions comprising oligonucleotides suitable to be used in the processes mentioned before. The invention further provides nucleotide compositions obtainable by the processes of the invention and uses thereof. The invention further provides compositions comprising (i) a virus-like particle, wherein said virus-like particle is a virus-like particle of an RNA bacteriophage, and (ii) an oligonucleotide, wherein said oligonucleotide is packaged into said virus-like particle, wherein said compositions are obtainable by the processes of the invention and wherein said compositions preferably comprises a purity of at least 98%, most preferably of at least 99%. | 2014-07-03 |
20140186406 | Treatment of Infection - The invention relates to compositions including a substance useful as an adjuvant for potentiating an immune response, and methods of using the composition in individuals with infections of tissue within or adjacent to a transformation zone, such as the transformation zone of the cervix or anal canal. | 2014-07-03 |
20140186407 | C-Met Modulator Pharmaceutical Compositions - Pharmaceutical compositions and unit dosage forms comprising Compound I are disclosed. | 2014-07-03 |
20140186408 | CRYSTAL POLYMORPH OF MAGNESIUM GLYCINATE DIHYDRATE AND PROCESS FOR ITS PREPARATION - Embodiments of the invention provide solid forms of magnesium glycinate dihydrate and compositions thereof, which are useful for treating hyperphosphatemia and which exhibit desirable characteristics for the same. The invention further provides processes for the production of solid forms of magnesium glycinate dihydrate. | 2014-07-03 |
20140186409 | NOVEL LACTIC ACID BACTERIA AND COMPOSITIONS CONTAINING THEM - The invention relates to a microorganism, of the order of lactic acid bacteria or analog, fragment, derivative, mutant or combination thereof. Said microorganism, or analog, fragment, derivative, mutants or combinations thereof can be co-aggregated with at least | 2014-07-03 |
20140186410 | DRYABLE ADHESIVE COATING - A dried adhesive coating is manufactured by steps of: a) providing a composition comprising a solution of a polymer, wherein at least 1 wt % of said polymer based on the molecular weight Mw are catechol groups, and wherein the concentration of said polymer in said composition is from 0.1 to 250 mg/ml, b) adjusting the pH of the composition to a value from about ó to about 7, either (i) before applying the composition to the surface to be coated or (ii) after applying the composition to the surface to be coated, c) applying the composition to the surface to be coated to obtain an adhesive coating on at least a part of the surface, and d) drying the coating. | 2014-07-03 |
20140186411 | LOW VISCOSITY META-STABLE PHOTOPROTECTION COMPOSITION - A meta-stable photoprotective composition, a product including the meta-stable composition, and a method of protecting a keratinous substrate from UV radiation by applying the product are provided. The meta-stable photoprotective composition includes at least one water-in-oil emulsifier having a hydrophilic-lipophilic balance (HLB) of less than 6, at least one non-ionic oil-in-water emulsifier having an HLB of greater than 9, at least one ionic surfactant, and at least one sunscreen active ingredient. The weight ratio of the at least one non-ionic oil-in-water emulsifier to the at least one water-in-oil emulsifier is about 0.2 to about 2.0. The meta-stable composition converts from an oil-in-water (O/W) emulsion to a water-in-oil (W/O) emulsion upon rubbing. | 2014-07-03 |
20140186412 | DETERGENT COMPOSITIONS DISPERSED IN PERSONAL CARE PRODUCTS COMPRISING A SORBENT CARRIER - Detergent compositions and detergent compositions dispersed in personal care products are provided herein. In one embodiment, a detergent composition is provided and comprises a sorbent carrier. The detergent composition also includes a sorbed component including an acid and a surfactant. The sorbed component is sorbed by the sorbent carrier. | 2014-07-03 |
20140186413 | PREPARATION METHOD OF CORE-SHELL STRUCTURED FIBROUS SCAFFOLDS - The present invention relates to a preparation method for core-shell structured fibrous scaffolds, and more specifically to preparing a core part composition and a shell part composition that each have different constitutions by adding calcium phosphate cement and a protein, drug of combination thereof to alginate solution, and then inserting the above core part composition and shell part composition to internal and external nozzle of concentric nozzle respectively to inject into calcium ion aqueous solution and thereby hardening them, thus preparing core-shell structured rapidly setting Alg/α-TCP scaffolds capable of controllably releasing a protein or drug. | 2014-07-03 |
20140186414 | METHODS AND USES FOR EX VIVO TISSUE CULTURE SYSTEMS - The technology described herein is directed to methods and devices that can be used to induce functional organ structures to form within an implantation device by implanting it in vivo within the body of a living animal, and allowing cells and tissues to impregnate the implantation device and establish normal microenvironmental architecture and tissue-tissue interfaces. Then the contained cells and tissues can be surgically removed intact and either transplanted into another animal or maintained ex vivo by perfusing it through one or more of the fluid channels with medium and/or gases necessary for cell survival. | 2014-07-03 |
20140186415 | POLYMER COMPOSITION AND POLYMER MATERIAL - A polymer composition including a polymer having a hydroxyl group and a histidine or a histidine derivative grafted to the polymer having a hydroxyl group. A polymer material is also provided, including a polymer composition which includes a polymer having a hydroxyl group, and a histidine or a histidine derivative grafted to the polymer having a hydroxyl group. | 2014-07-03 |
20140186416 | METHOD FOR REPAIRING OR REPLACING DAMAGED TISSUE - A method for repairing or replacing damaged tissue, or for providing post-surgical augmentation, comprising administering a pliable biocompatible material and a physiologically acceptable suspending agent to a patient is disclosed. Copolymers of unsubstituted acrylate and substituted acrylate are disclosed as pliable biocompatible materials. | 2014-07-03 |
20140186417 | Tailored Aliphatic Polyesters for Stent Coatings - An aliphatic polyester polymer for stent coating is described. | 2014-07-03 |
20140186418 | METHOD FOR REPAIRING OR REPLACING DAMAGED TISSUE - A method for repairing or replacing damaged tissue, or for providing post-surgical augmentation, comprising administering a pliable biocompatible material and a physiologically acceptable suspending agent to a patient is disclosed. Copolymers of unsubstituted acrylate and substituted acrylate are disclosed as pliable biocompatible materials. | 2014-07-03 |
20140186419 | USE OF SDF-1 TO MITIGATE SCAR FORMATION - The subject matter provided herein relates to method for inhibiting or mitigating scar formation in a wound of the skin, by increasing the concentration of SDF-1 in, or proximate to, the wound. As described herein SDF-1 protein or an SDF-1 expression vector can be administered to a wound or the area proximate a wound by providing a therapeutically effective amount of SDF-1 protein or an SDF-1 expression vector. | 2014-07-03 |
20140186420 | DRUG CORES FOR SUSTAINED RELEASE OF THERAPEUTIC AGENTS - A solid drug core insert can be manufactured by injecting a liquid mixture comprising a therapeutic agent and a matrix precursor into a sheath body. The injection can be conducted at subambient temperatures. The mixture is cured to form a solid drug-matrix core. The therapeutic agent can be a liquid at about room temperature that forms a dispersion of droplets in the matrix material. A surface of the solid drug core is exposed, for example by cutting the tube, and the exposed surface of the solid drug core releases therapeutic quantities of the therapeutic agent when implanted into the patient. In some embodiments, the insert body inhibits release of the therapeutic agent, for example with a material substantially impermeable to the therapeutic agent, such that the therapeutic quantities are released through the exposed surface, thereby avoiding release of the therapeutic agent to non-target tissues. | 2014-07-03 |
20140186421 | EXTENDED BUPRENORPHINE TRANSDERMAL DELIVERY COMPOSITIONS AND METHODS FOR USING THE SAME - Aspects of the invention include extended transdermal delivery devices for delivering buprenorphine to a subject for an extended period of time, where the transdermal delivery devices include buprenorphine, an α-hydroxy acid and a pressure sensitive adhesive. In certain instances, buprenorphine, α-hydroxy acid and the pressure sensitive adhesive are provided as a single matrix layer formulation. Also provided are methods of using the subject extended transdermal delivery devices, as well as kits containing the extended transdermal delivery device. | 2014-07-03 |
20140186422 | PROPYNYLAMINOINDAN TRANSDERMAL COMPOSITIONS - Propynylaminoindan (e.g., Rasagiline) transdermal compositions are provided. Aspects of the transdermal compositions include a matrix which includes the propynylaminoindan, a pressure sensitive adhesive that includes an acrylate copolymer and a cationic acrylic copolymer. Also provided are methods of using the transdermal compositions and kits containing the transdermal compositions. | 2014-07-03 |
20140186423 | Transdermal Patch Having Ultrasound Transducer for Administering Thrombolytic Reagents to Patients Having a Protein Misfolding Disease - The present invention relates to a method and device for treating patients with a Protein Misfolding Disease by chronically administering an effective dose of a thrombolytic reagent and/or a thrombolytic reagent regulator over an intermittent period of time. The thrombolytic reagents degrade the misfolded proteins that accumulate and that can become toxic in such patients. The thrombolytic reagent regulators increase the catalytic efficiency of the thrombolytic reagents to reduce the amount of thrombolytic reagents necessary for an effective dose. The administration is administered transdermally via a transdermal patch that is equipped with an ultrasound transducer for enhancing the penetration of the thrombolytic reagent and thrombolytic reagent regulator into the bloodstream of a patient by increasing the permeability of the patient's skin. | 2014-07-03 |
20140186424 | MULTI-POLYMER COMPOSITIONS FOR TRANSDERMAL DRUG DELIVERY - Multi-polymer compositions for the transdermal delivery of drugs, such as amine-functional drugs, in a flexible, finite form are described. The compositions comprise a polymer matrix that includes a drug or a pharmaceutically acceptable salt thereof and a polymer matrix comprising acrylic polymer(s), polyisobutylene polymer(s) and styrene-isoprene-styrene block copolymer(s). Methods of manufacturing and methods of using the compositions also are described. | 2014-07-03 |
20140186425 | LAYERED ADHESIVE CONSTRUCT - A layered adhesive construct includes a backing layer and a layer of a pressure sensitive, hot melt processable adhesive composition. The adhesive composition includes a polar plasticising oil or a combination of polar plasticising oils in a content above 10% (w/w), and 10-50% (w/w) of a polar polyethylene copolymer. The polyethylene copolymer has a melt flow index below 2 g/10 min (190° C./21.1N), and the polar plasticising oil is a liquid rosin derivative, animal oils and derivatives, esters, ethers, glycols, poly propylene oxide, or alpha-butoxy-polyoxypropylene. | 2014-07-03 |
20140186426 | CATALYTIC DELIVERY NANOSUBSTRATES (CDNS) FOR HIGHLY EFFICIENT DELIVERY OF BIOMOLECULES - This invention relates, e.g., to a molecular delivery system comprising A. a substrate having a nanostructured surface region which comprises a plurality of nanostructures and, covalently attached to the substrate, multiple copies of a first member of a binding pair; and B. at least one vector nanoparticle which comprises, encapsulated therein, a molecule of interest, and on its surface, multiple copies of second member of the binding pair. Methods of using the molecular delivery system to deliver a molecule of interest to a cell are also described. | 2014-07-03 |
20140186427 | ORODISPERSIBLE FILMS FOR THE MANUFACTURING OF INDIVIDUALISED MEDICINE OR FOR LARGE SCALE PRODUCTION - The present invention pertains to oral applicable therapeutic dosage forms, in particular to orodispersible films. The present invention especially is directed to orodispersible films comprising a base layer substantially free of therapeutically active agents and a top layer comprising the desired therapeutically active agents. The present invention also concerns suitable base layers for such orodispersible films as well as therapeutical uses thereof and methods for manufacturing them. | 2014-07-03 |
20140186428 | PATCH AND METHOD FOR PRODUCING THE SAME - A method for producing a patch comprising a support layer and an adhesive agent layer arranged on at least one surface of the support layer, the method comprising:
| 2014-07-03 |
20140186429 | RECOMBINANT PROTEIN, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, AND METHOD OF BIOSYNTHESIZING - The present invention provides a method of biosynthesizing a recombinant protein containing the biologically active peptide, the pharmaceutical composition containing the recombinant protein as well as the preparation of the recombinant protein. Simply speaking the consecutively multiple copies of the bioactive peptide are replaced in the amino acid sequence of a recombinant protein (so called peptide-protein). Then, a high concentration and high yield of the peptide-protein containing the consecutively multiple copies of the bioactive peptide is produced by the biosafety and edible strain of yeast without any endotoxin contamination. | 2014-07-03 |
20140186430 | COCHLEATE COMPOSITIONS DIRECTED AGAINST EXPRESSION OF PROTEINS - Disclosed herein are novel siRNA-cochleate and morpholino-cochleate compositions. Also disclosed are methods of making and using siRNA-cochleate and morpholino-cochleate compositions. | 2014-07-03 |
20140186431 | COMBINED MESENCHYMAL STEM CELL TRANSPLANTATION AND TARGETED DELIVERY OF VEGF FOR TREATMENT OF MYOCARDIAL INFARCTION - Compositions and kits useful for the treatment of myocardial infarction comprise (i) P-selectin-targeted carriers (e.g., P-selectin-targeted liposomes, quantum dots or biodegradable nanoparticles) comprising VEGF and (ii) MSCs. | 2014-07-03 |
20140186432 | MODIFIED POLYNUCLEOTIDES ENCODING CITED4 - The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules. | 2014-07-03 |
20140186433 | Cosmetic Treatment System and Methods - A cosmetic treatment system is provided having ingredients that may prevent signs of aging, improve the aesthetic appearance of skin, and promote recovery from environmental stresses. The composition includes natural ingredients, including at least one ingredient or extract from rosemary; at least one ingredient or extract from | 2014-07-03 |
20140186434 | ANTI-TUMOR NECROSIS FACTOR ALPHA (TNF-A) ANTIBODY USED AS A TARGETING AGENT TO TREAT ARTHRITIS AND OTHER DISEASES - This invention describes the use of anti-TNF-a antibody as a targeting agent attached to liposomes incorporating anti-inflammatory drugs to treat arthritis and other inflammatory diseases. A variety of steroidal and non-steroidal drugs and disease modifying drugs and other anti-inflammatory compounds may be incorporated into the anti-TNF-a coated liposomes. The anti-TNF-a coated drug liposomes will accumulate within the inflamed site where the drug is released for maximum therapeutic effect. Other nanosized drug delivery vehicles such as dendrimers, micelles, nanocapsules and nanoparticles may be similarly coated with anti-TNF-a antibody and used to deliver the drug to the site of inflammation. Also in lieu of the anti-TNF-a antibody other TNF-a binding agents such as aptamers and binding peptides may be used to coat the various nanosized drug delivery vehicles such as micelles, dendrimers, nanocapsules and nanoparticles in order to deliver the drug to the site of inflammation. | 2014-07-03 |
20140186435 | SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR (STNF-R) USED AS A TARGETING AGENT TO TREAT ARTHRITIS AND OTHER DISEASES - This invention describes the use of sTNF-R as a targeting agent attached to liposomes incorporating anti-inflammatory drugs to treat arthritis and other inflammatory diseases. A variety of steroidal and non-steroidal drugs and disease modifying drugs and other anti-inflammatory compounds may be incorporated into the sTNF-R coated liposomes. The sTNF-R coated drug liposomes will accumulate within the inflamed site where the drug is released for maximum therapeutic effect. Other nanosized drug delivery vehicles such as dendrimers, micelles, nanocapsules and nanoparticles may be similarly coated with sTNF-R and used to deliver the drug to the site of inflammation. | 2014-07-03 |
20140186436 | ORAL DELIVERY OF ENZYMES BY NANOCAPSULES FOR TARGETED METABOLISM OF ALCOHOL OR TOXIC METABOLITES - The invention disclosed herein includes nanocomplexes that are designed include enzymes that have complementary functional attributes and methods for using these nanocomplexes. Illustrative examples include nanocomplexes that comprise both an alcohol oxidase enzyme as well as a catalase enzyme. These nanocomplexes can be used in methods designed to lower blood alcohol levels in vivo, and/or to break down the toxic byproducts of alcohol metabolism. Consequently these nanocomplexes can be used to treat a variety of conditions resulting from the consumption of alcohol, including for example, acute alcohol intoxication. | 2014-07-03 |
20140186437 | ORAL DOSAGE FORMS WITH THERAPEUTICALLY ACTIVE AGENTS IN CONTROLLED RELEASE CORES AND IMMEDIATE RELEASE GELATIN CAPSULE COATS - The present invention relates to oral dosage form with active agents in controlled release cores and in immediate release gelatin capsule coats. | 2014-07-03 |
20140186438 | COMPOSITIONS COMPRISING EPA AND OBETICHOLIC ACID AND METHODS OF USE THEREOF - In various embodiments, the present invention provides compositions comprising eicosapentaenoic acid or a derivative thereof and obeticholic acid or a derivative thereof. In other embodiments, the present invention provides methods of treating and/or preventing NASH and/or PBC comprising co-administering to a subject in need thereof eicosapentaenoic acid or a derivative thereof and obeticholic acid or a derivative thereof. | 2014-07-03 |
20140186439 | STABLE COMPOSITIONS OF FAMOTIDINE AND IBUPROFEN - Stable pharmaceutical compositions of famotidine and ibuprofen in a single unit dosage form are disclosed herein. The compositions comprise a famotidine core having a reduced or minimal surface area surrounded by a layer of ibuprofen. In some embodiments, the ibuprofen is in direct physical contact with the famotidine. | 2014-07-03 |